Bellevue Group Ag Black Diamond Therapeutics, Inc. Transaction History
Bellevue Group Ag
- $4.31 Billion
- Q1 2025
A detailed history of Bellevue Group Ag transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 2,733,547 shares of BDTX stock, worth $8.86 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
2,733,547
Previous 8,517,839
67.91%
Holding current value
$8.86 Million
Previous $18.2 Million
76.76%
% of portfolio
0.1%
Previous 0.36%
Shares
12 transactions
Others Institutions Holding BDTX
# of Institutions
95Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$33.7 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$18.1 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$14.4 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$10.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.36MShares$7.64 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $118M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...